Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC

Nicole DeFeudis

Editor

Keytruda’s accelerated approval in a common form of liver cancer looked shaky after the drug failed on two survival measures in a confirmatory study almost …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC

Nicole DeFeudis

Editor

Sign up to read this article for free.

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Novartis turns to BioAge for new targets based on longevity and exercise

Exclusive: Color Health alums raise $10M for new startup, using AI for regulatory work

Al­most three years af­ter whiff­ing in a con­fir­ma­to­ry study, Mer­ck touts new da­ta for Keytru­da in HCC

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Novartis turns to BioAge for new targets based on longevity and exercise

Exclusive: Color Health alums raise $10M for new startup, using AI for regulatory work